Telix Pharmaceuticals Limited (TLX)
Fair ValueFundamental
33
Price
$9.15
Market Cap
$3.40B
Part 1 · What the company is worth
Overview
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.20B
Fiscal year ended 12/31/2025
Net Income
$-10M
Fiscal year ended 12/31/2025
Free Cash Flow
$-63M
Total Equity
$486M
Total Liabilities
$580M
Current Ratio
2.01
Interest Coverage
-
Debt/EBITDA
8.31
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$8.92
Current Price
$9.15
Margin of Safety
-2.6%
Fair Value Range
$5.80 - $12.04
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
111.44
ROE
7.4%
P/B Ratio
6.99
P/FCF
-
Gross Margin
47.6%
ROIC
6.4%
Profitability Radar
Value Creation (Economic Moat)
ROIC
6.4%
WACC
8.5%
ROIC − WACC
-2.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (4)
- ROIC 6.4%
- Gross margin 47.6%
- Debt/equity ratio
- Current ratio
Failed (7)
- Price CAGR -14.46%
- P/B ratio 6.99
- Positive free cash flow
- Debt/EBITDA
- DCF valuation (Unknown)
- Net margin trend -0.8% vs 6.4%
- Piotroski F-Score 0/9
Unavailable (15)
- EPS data insufficient
- P/FCF –
- Dividend payout –
- Operating margin –
- CapEx intensity
- Interest coverage
- Return on tangible assets
- Low reliance on intangibles
- Price below Graham Number
- ROE
- Revenue growth 5Y
- Earnings surprise
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
- Share dilution (missing share count)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer | 60 |
| Dr. Paul Schaffer | SVP of Research & Development | - |
| Mr. Craig Ulrick | Chief Information Officer | - |
| Ms. Kyahn Williamson B.A. | Senior Vice President of Corporate Communications & Investor Relations | - |
| Mr. Christian Krautkramer J.D. | Group General Counsel | - |
| Thomas Fromm | Vice President of Sales | - |
| Ms. Meredith Crowe BDES | Senior Vice President of Global People & Culture | - |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor | 60 |
| Ms. Odile Jaume M.B.A., M.Sc. | Advisor | - |
| Mr. Raphael Ortiz L.L.B., M.B.A. | Chief Executive Officer of Telix International | - |
Documents
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much TLX moves, measured on its daily prices.
More volatile than 85% of the tracked stocks (90-day volatility).
- Volatility 30d
- 72.0%
- Volatility 90d
- 59.1%
- Beta vs S&P 500 (1y)
- 0.94Correlation 0.22
- Max drawdown (12m)
- -41.5%
- ATR (14d, % of price)
- 5.06%
Earnings reactions
How TLX moved around its past quarterly results.
No earnings releases recorded yet for TLX. This can happen with recent listings or with companies that do not file 8-K reports with the SEC.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on TLX and what the price did next.
- 4/14/2026NegativeTelix Pharma Upsizes Convertible Bond Deal to $600 Million
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
- 2/26/2026Positive1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth
- +1 day
- +11.3%
- +3 days
- +4.8%
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for TLX.
- 4/14/2026NEGATIVETelix Pharma Upsizes Convertible Bond Deal to $600 Million
Telix Pharmaceuticals Ltd. successfully upsized its convertible bond offering to $600 million, exceeding initial expectations and marking Australia's largest such deal this year. Despite the strong demand for the debt issuance, indicating investor confidence in the company's future prospects, Telix's shares experienced a decline. This suggests a potential short-term market reaction to the dilutionary nature of convertible bonds or profit-taking following the announcement.
- 2/26/2026POSITIVE1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth
Telix Pharmaceuticals, a company specializing in radiopharmaceuticals for cancer diagnosis and treatment, is drawing attention as a potential high-growth investment. Analysts suggest its innovative approach to cancer imaging breakthroughs could unlock significant long-term value for investors. The firm's focus on advanced medical solutions positions it favorably within the burgeoning healthcare sector, promising substantial returns for those looking to capitalize on cutting-edge pharmaceutical developments. This outlook highlights Telix as a compelling opportunity for generational wealth creation through medical innovation.